Kyverna Therapeutics Inc (NASDAQ: KYTX) on Monday, soared 12.48% from the previous trading day, before settling in for the closing price of $5.77. Within the past 52 weeks, KYTX’s price has moved between $3.92 and $35.06.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -37.90%. The company achieved an average annual earnings per share of 96.32%. With a float of $18.70 million, this company’s outstanding shares have now reached $43.17 million.
The extent of productivity of a business whose workforce counts for 96 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Kyverna Therapeutics Inc (KYTX) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Kyverna Therapeutics Inc is 56.68%, while institutional ownership is 31.25%. The most recent insider transaction that took place on Feb 12 ’24, was worth 5,568,992. In this transaction 10% Owner of this company bought 253,136 shares at a rate of $22.00, taking the stock ownership to the 252,553 shares. Before that another transaction happened on Feb 12 ’24, when Company’s 10% Owner bought 450,000 for $22.00, making the entire transaction worth $9,900,000. This insider now owns 3,163,868 shares in total.
Kyverna Therapeutics Inc (KYTX) Latest Financial update
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -75.82 earnings per share (EPS) for the period falling under the consensus outlook (set at -3.2) by -72.62. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.72 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 96.32% per share during the next fiscal year.
Kyverna Therapeutics Inc (NASDAQ: KYTX) Trading Performance Indicators
Kyverna Therapeutics Inc (KYTX) is currently performing well based on its current performance indicators. A quick ratio of 10.50 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.07, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -3.69 in one year’s time.
Technical Analysis of Kyverna Therapeutics Inc (KYTX)
The latest stats from [Kyverna Therapeutics Inc, KYTX] show that its last 5-days average volume of 0.53 million was superior to 0.46 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 86.97%. Additionally, its Average True Range was 0.53.
During the past 100 days, Kyverna Therapeutics Inc’s (KYTX) raw stochastic average was set at 34.36%, which indicates a significant decrease from 78.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 117.41% in the past 14 days, which was higher than the 83.54% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.06, while its 200-day Moving Average is $12.37. Now, the first resistance to watch is $7.14. This is followed by the second major resistance level at $7.80. The third major resistance level sits at $8.39. If the price goes on to break the first support level at $5.89, it is likely to go to the next support level at $5.30. The third support level lies at $4.64 if the price breaches the second support level.
Kyverna Therapeutics Inc (NASDAQ: KYTX) Key Stats
Market capitalization of the company is 280.18 million based on 43,172K outstanding shares. Right now, sales total 0 K and income totals -60,370 K. The company made 0 K in profit during its latest quarter, and -34,490 K in sales during its previous quarter.
